Virax Biolabs Group Ltd (VRAX) Return on equity 2023–2025
Virax Biolabs Group Ltd (VRAX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-106.4%FY2025 · since FY2023: -59.8% → -106.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -106.4% | +19.1 pp |
| FY2024 | -125.5% | -65.7 pp |
| FY2023 | -59.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More VRAX financial trends
VRAX RevenueVRAX Net incomeVRAX Net marginVRAX Gross profitVRAX Gross marginVRAX Operating incomeVRAX Operating marginVRAX Operating cash flowVRAX Free cash flowVRAX Capital expendituresVRAX Stock buybacksVRAX Dividends paidVRAX Total assetsVRAX Total liabilitiesVRAX Shareholders’ equityVRAX overview →